While there are currently no therapies directly targeting mutated genes in MDS, hematologic malignancies harboring SF3B1 and SRSF2 mutations have been reported to be sensitive to splicing factor 3B subunit 1 (SF3b155) inhibitors, which are in clinical development [49, 50]. This evidence concerns the gene SRSF2 and myelodysplastic syndrome.